BRIVA-ONE study: 12-month outcomes of brivaracetam monotherapy in clinical practice.

Objective: This study investigated the effectiveness and tolerability of brivaracetam (BRV) monotherapy in a large series of patients with epilepsy.

Method: This was a multicenter, retrospective, observational, non-interventional study in 24 hospitals across Spain. Patients aged ≥18 years who started on BRV monotherapy, either as first-line or following conversion, at least 1 year before database closure were included.

Identifying risk for status epilepticus with the ADAN scale: a prospective multicenter validation study.

Objectives: Status epilepticus (SE) is a serious event associated with high mortality. This study aims to validate the recently developed ADAN (Abnormal speech, ocular Deviation, Automatisms, and Number of motor epileptic seizures) scale for detecting high risk for SE.

Material And Methods: Prospective, multicenter, observational study in adults with suspected epileptic seizures.

The usefulness of NDDI-E and QOLIE-10 scales for the screening of major depressive disorders in patients with epilepsy in video-EEG units.

Objective: Mood disorders in patients with epilepsy are common, with depression being the most prevalent. However, this comorbidity is often underdiagnosed. The systematic use of scales such as NDDI-E and QOLIE-10 in prolonged video-EEG monitoring units could be a useful tool for the detection of this comorbidity.

Real-life evidence about the use of intravenous brivaracetam in urgent seizures: The BRIV-IV study.

Purpose: Urgent seizures are a medical emergency for which new therapies are still needed. This study evaluated the use of intravenous brivaracetam (IV-BRV) in an emergency setting in clinical practice.

Methods: BRIV-IV was a retrospective, multicenter, observational study.